CAR-T therapy for leukemia or lymphoma in the brain
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests CAR-T cells—immune cells engineered to recognize cancer—for people whose leukemia or lymphoma has spread to the central nervous system (the brain/spinal fluid). It may help shrink or control hard-to-treat (relapsed or refractory) cancers in the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have specific blood cancers: B-ALL (age ~3–70) or B-cell lymphoma (age ~18–75).
- Your cancer is back or not responding to treatment, and it involves CD19 (for B-ALL) or matches certain lymphoma types.
- Doctors think or confirmed the cancer has reached the brain/spinal fluid.
- You can meet basic health checks: breathing is okay, heart pumping is strong enough, and you have enough time to live (at least 3 months).
- No major recent steroid treatment, no prior CAR-T or other gene-modified T-cell therapy.
- You are not pregnant or breastfeeding, and you do not have certain serious infections or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
This trial tests a new CAR-T cell therapy that targets a protein called CD19 on leukemia cells. It's designed for people with relapsed or refractory B-cell acute lymphoblastic leukemia (a type of blood cancer) that hasn't responded to standard treatments.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.